|1.||Siena, Salvatore: 24 articles (10/2015 - 05/2005)|
|2.||Sartore-Bianchi, Andrea: 16 articles (10/2015 - 05/2005)|
|3.||Bardelli, Alberto: 15 articles (07/2015 - 05/2005)|
|4.||Van Cutsem, Eric: 14 articles (12/2015 - 01/2007)|
|5.||Peeters, Marc: 14 articles (12/2015 - 05/2007)|
|6.||Di Nicolantonio, Federica: 13 articles (07/2015 - 05/2005)|
|7.||Tabernero, Josep: 11 articles (11/2015 - 12/2008)|
|8.||Hecht, J Randolph: 11 articles (09/2015 - 01/2006)|
|9.||Oliner, Kelly S: 10 articles (12/2015 - 11/2010)|
|10.||Amado, Rafael G: 10 articles (04/2009 - 03/2007)|
|1.||Colorectal Neoplasms (Colorectal Cancer)
09/01/2015 - "Panitumumab has proven efficacy in patients with metastatic or locally advanced colorectal cancer patients, provided that they have no activating KRAS mutation in their tumour. "
12/03/2007 - "In a randomised phase 3 trial, panitumumab significantly improved progression-free survival (PFS) in patients with refractory metastatic colorectal cancer (mCRC). "
05/01/2007 - "Panitumumab significantly improved PFS with manageable toxicity in patients with chemorefractory colorectal cancer."
11/01/2015 - "Although the anti-EGFR monoclonal antibody panitumumab is effective in treating colorectal cancer, the occurrence of severe skin disorders often discontinues therapy. "
10/01/2012 - "Our findings suggested that panitumumab has great potential for effective treatment of patients with unresectable stageIV colorectal cancer."
01/01/2014 - "In patients with WT KRAS tumors, panitumumab-FOLFIRI significantly improved PFS versus FOLFIRI [median 6.7 versus 4.9 months; hazard ratio (HR) 0.82 [95% confidence interval (CI) 0.69, 0.97]; P = 0.023]. "
01/01/2012 - "The LS-174T tumor AUC of 204.13 ± 9.67 was significantly greater (P < 0.001) than the LS-174T tumor AUC of 36.45 ± 1.39 obtained from mice coinjected with 0.1 mg of panitumumab for blocking the target. "
06/01/2014 - "However, active initiation as first-line treatment should be considered for cases in which resection of metastatic foci can be expected from tumor reductions due to panitumumab. "
03/01/2012 - "Improved tumor response was also observed with the addition of panitumumab to FOLFIRI. "
09/01/2011 - "Panitumumab plus FOLFIRI numerically improved objective response rate, PFS, and OS in favor of patients with wild-type KRAS tumors. "
|3.||Sarcoma (Soft Tissue Sarcoma)
12/01/2015 - "Panitumumab and cetuximab have improved tumour response rate, progression-free survival, and OS in mCRC patients in whom the RAS (Rat Sarcoma) gene is of Wild Type (WT) status. "
10/01/2012 - "In the Greek NHS and Social Security Sickness Fund setting, panitumumab monotherapy potentially constitutes a cost-saving option (versus cetuximab monotherapy) in the management of patients with mCRC and no mutation of Kirsten rat sarcoma viral oncogene homolog."
06/01/2013 - "The randomized first-line trials, including the CRYSTAL trial, the OPUS trial, and the PRIME trial, have demonstrated the significant efficacy of cetuximab or panitumumab in patients with v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) wild-type tumors. "
10/01/2012 - "The aim of this study was to conduct a cost-minimization analysis comparing panitumumab with cetuximab in the treatment of patients with epidermal growth factor receptor-expressing mCRC with nonmutated (wild-type) Kirsten rat sarcoma viral oncogene homolog in Greece. "
11/01/2015 - "The aim of the study was to investigate the efficacy and tolerability of panitumumab, a fully human antiepidermal growth factor receptor monoclonal antibody, in combination with pemetrexed/cisplatin in patients with stage IIIB to IV primary nonsquamous non-small-cell lung cancer and wild type V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS). "
06/01/2013 - "Results from the primary analysis of a phase 3, randomized, controlled study showed a statistically significant improvement in progression-free survival for patients receiving panitumumab; however, overall survival was confounded by best supportive care (BSC) patients that crossed over to panitumumab therapy after disease progression. "
01/01/2012 - "Treatment was continued until disease progression, death, inability to tolerate panitumumab, or study withdrawal. "
06/07/2011 - "As the trial design allowed patients on BSC alone to receive panitumumab after disease progression, which confounded overall survival (OS), the focus of this analysis was on PFS. "
08/01/2008 - "In a randomized phase 3 study (463 patients), panitumumab almost halved the risk of disease progression/death vs. a control group receiving only best supportive care (hazard ratio 0.54; 95% CI: 0.44-0.66; P < 0.0001). "
01/01/2008 - "This open-label extension study evaluated panitumumab monotherapy in BSC patients with radiographically documented disease progression in the phase 3 study. "
|5.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
10/01/2013 - "RTOG 0839 is a Phase II study of pre-operative chemoradiotherapy with or without panitumumab in potentially operable locally advanced non-small cell lung cancer (NSCLC). "
10/01/2013 - "Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab."
09/01/2015 - "Overcoming Resistance Without the Risk of Reaction: Use of Afatinib and Panitumumab in Two Cases of Epidermal Growth Factor Receptor--Mutated Non--Small-Cell Lung Cancer With T790M Mutations."
06/01/2009 - "We investigated the activity of panitumumab, a fully human anti-EGFR monoclonal antibody, in vitro in mutant EGFR-expressing non-small cell lung carcinoma (NSCLC) cells and in vivo with chemotherapy in xenograft models. "
07/01/2006 - "Panitumumab has demonstrated efficacy as monotherapy and with standard chemotherapeutic agents in a wide variety of cancer types, including non-small-cell lung cancer, renal, and colorectal cancer (CRC). "
|4.||Epidermal Growth Factor Receptor (EGF Receptor)
|8.||Leucovorin (Folinic Acid)
|9.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)
|3.||Combination Drug Therapy (Combination Chemotherapy)
|4.||Molecular Targeted Therapy